DAX23.092 -0,8%Est505.515 -1,0%MSCI World4.343 -0,1%Top 10 Crypto11,61 -4,3%Nas22.216 +0,6%Bitcoin73.727 -1,9%Euro1,1506 -0,2%Öl62,37 -1,3%Gold4.085 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 RENK RENK73 DroneShield A2DMAA Siemens Energy ENER6Y Amazon 906866 Deutsche Telekom 555750 Tesla A1CX3T Infineon 623100 Alphabet A (ex Google) A14Y6F Lufthansa 823212 Palantir A2QA4J TKMS thyssenkrupp Marine Systems TKMS00 SAP 716460 Siemens 723610
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht bei über 23.000 Punkten ins Wochenende -- Portfolio von NVIDIA -- Bitcoin & Co. tiefrot -- D-Wave, SAP, Novo Nordisk, Siemens Energy, DroneShield, Rheinmetall, RENK, HENSOLDT im Fokus
Top News
Suchst Du einen Online Broker, der mehr bietet? Clever und flexibel traden mit finanzen.net ZERO Suchst Du einen Online Broker, der mehr bietet? Clever und flexibel traden mit finanzen.net ZERO
Hunderte Euro zu viel gezahlt? 8 Broker im Ordergebühren-Vergleich Hunderte Euro zu viel gezahlt? 8 Broker im Ordergebühren-Vergleich
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Für alle, die mehr wollen: Bonus-Zertifikate der LBBW. Jetzt mehr erfahren!

Biohaven Research Aktie

Kaufen
Verkaufen
8,70 EUR +0,40 EUR +4,82 %
BER
9,87 USD +0,23 USD +2,39 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.867,23 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DVH7

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINVGG1110E1079

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolBHVN

Biohaven Research Aktien News

DatumMeistgelesen
PR NewswireBiohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
PR NewswireFDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswireBiohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswireBiohaven Ltd. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BHVN
PR NewswireLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 12, 2025 in Biohaven Ltd. Lawsuit - BHVN
PR NewswireBiohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments
PR NewswireBHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswireBHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswireINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
PR NewswireShareholders of Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN
PR NewswireBHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswireBHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireBHVN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biohaven Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswirePomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
PR NewswireRosen Law Firm Urges Biohaven Ltd. (NYSE: BHVN) Stockholders to Contact the Firm for Information About Their Rights
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
PR NewswireBiohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor
PR NewswireBiohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient...
PR NewswireBiohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to ...
PR NewswireFDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia
PR NewswireBiohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
PR NewswireBiohaven Announces Investment up to $600 Million by Oberland Capital
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN
PR NewswireBiohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd - BHVN

Biohaven Research News

Biohaven Research News: auf dieser Seite finden Sie alle Biohaven Research News und Nachrichten zur Biohaven Research Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Biohaven Research News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Biohaven Research News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.